

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6553825

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GWONG-JEN J. CHANG	06/18/2017
BRENT S. DAVIS	06/19/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
<b>Street Address:</b>	6011 EXECUTIVE BOULEVARD, SUITE 325, MSC 7660
<b>Internal Address:</b>	OTT, NATIONAL INSTITUTES OF HEALTH
<b>City:</b>	BETHESDA
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20892-7660
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17168889
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	5035955300
<b>Email:</b>	gina.horton@klarquist.com
<b>Correspondent Name:</b>	JODI L. CONNOLLY, KLARQUIST SPARKMAN LLP
<b>Address Line 1:</b>	121 SW SALMON ST., SUITE 1600
<b>Address Line 2:</b>	ONE WORLD TRADE CENTER
<b>Address Line 4:</b>	PORTLAND, OREGON 97204-2927
<b>ATTORNEY DOCKET NUMBER:</b>	4239-96528-08
<b>NAME OF SUBMITTER:</b>	JODI L. CONNOLLY
<b>SIGNATURE:</b>	/Jodi L. Connolly/
<b>DATE SIGNED:</b>	02/16/2021
<b>Total Attachments: 3</b>	
source=96528-08_Assignment#page1.tif	
source=96528-08_Assignment#page2.tif	



**ASSIGNMENT FOR NIH/FDA/CDC INVENTIONS AIA  
(NIH OR FDA OR CDC CO-INVENTORS ONLY)**

**WHEREAS**, we, Gwong-Jen J. Chang and Brent S. Davis, employees of the Centers for Disease Control and Prevention, are each employed by a component of the United States Department of Health and Human Services having an address at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660, and have made certain inventions as described and claimed in:

U.S. Provisional Patent Application No. 62/349,537, filed on June 13, 2016, entitled "NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS;" and

PCT Patent Application No. PCT/US2017/036762, filed on June 9, 2017, entitled "NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS,"

both applications are collectively referred to herein as "**The Patent Application(s)**"; and

**WHEREAS**, we are the inventors named in **The Patent Application(s)**; and

**WHEREAS**, the inventions described and claimed in **The Patent Application(s)** were made under conditions such as to entitle **THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services** [hereinafter **THE GOVERNMENT**] under Executive Order 10096 and its amendments, 35 U.S.C. §§200-201, §§206-207, and §210 and 37 C.F.R. Part 501 to the entire right, title, and interest in such inventions; and

**WHEREAS, THE GOVERNMENT** is desirous of acquiring all domestic and foreign right, title, and interest in the inventions described and claimed in **The Patent Application(s)**;

**NOW, THEREFORE**, having the legal obligation to assign our right, title and interest in the inventions described and claimed in **The Patent Application(s)** to **THE GOVERNMENT**, having a place of business at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660 and for consideration, the receipt and sufficiency of which are hereby acknowledged, we hereby assign and transfer to **THE GOVERNMENT**:

the entire right, title, and interest in and to any and all inventions described and claimed in **The Patent Application(s)** and any and all Letters Patent which may be granted thereon, and any and all continuations, divisions, reissues or extensions thereof; and


all rights to claim priority on the basis of **The Patent Application(s)** including but not limited to applications filed through the provisions of the Patent Cooperation Treaty ("PCT Applications"); and




all applications for Letters Patent that may be filed for any and all inventions described and claimed in **The Patent Application(s)** that may be filed in any foreign country and all Letters Patent that may be granted thereon in any foreign country and all extensions, renewals, and reissues thereof; and

any and all such Letters Patent as may be granted in the United States or any foreign country to be held by **THE GOVERNMENT** to the end of the term for which the same would have been held by the inventor(s) had this assignment not been made.

We further agree to make, execute, and deliver to **THE GOVERNMENT**, upon request, any and all papers, documents, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for improvements or reissues of Letters Patent, and to assist **THE GOVERNMENT** in every way as may be requested in protecting said invention.

IN WITNESS WHEREOF we subscribe our hands and seals on the dates shown below:

Inventor: Gwong-Jen J. Chang	
Date <u>6/18/2017</u>	<u>[Signature]</u> Inventor Signature
County of <u>Larimer</u>	
State of <u>Colorado</u>	
Subscribed and sworn to before me this <u>19th</u> day of <u>June</u> , <u>2017</u> .	
Seal	
	Notary Signature: <u>[Signature]</u>
	Notary Public for the State of <u>Colorado</u>
	My Commission Expires: <u>March 5, 2018</u>

Inventor: Brent S. Davis	
Date <u>6-19-17</u>	 Inventor Signature
County of <u>Larimer</u>	
State of <u>Colorado</u>	
Subscribed and sworn to before me this <u>19<sup>th</sup></u> day of <u>June</u> , <u>2017</u> .	
Seal	
	Notary Signature:  Notary Public for the State of <u>Colorado</u> My Commission Expires: <u>March 5, 2018</u>